Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

Summary Background Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, a transcription factor with protective roles at the epitheli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Alimentary pharmacology & therapeutics 2022-02, Vol.55 (4), p.401-411
Hauptverfasser:	Danese, Silvio, Levesque, Barrett G., Feagan, Brian G., Jucov, Alina, Bhandari, Bal Raj, Pai, Rish K., Taylor Meadows, Kristen, Kirby, Brian J., Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin, Van Biene, Courtney, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Clinical Trial Colitis, Ulcerative - therapy Corticosteroids Digestive system Double-Blind Method epithelial barrier dysfunction Epithelium Gastrointestinal tract HIF‐1α histologic remission Histopathology Humans Hypoxia Hypoxia-Inducible Factor 1, alpha Subunit - therapeutic use Immune response Immunosuppressive agents Inflammation Inflammatory bowel disease Leukocytes (neutrophilic) mucosal healing Nausea Oral administration Patients Pharmacodynamics Pharmacokinetics Placebos Randomised Clinical Trial Remission Induction Treatment Outcome Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!